Cargando…

Successful treatment with ivabradine in a β‐blocker‐refractory patient with acute decompensated heart failure with reduced ejection fraction

Ivabradine is an established treatment for chronic heart failure with reduced ejection fraction (HFrEF); however, it is not used for acute heart failure treatment. Negative inotropic effects (NIE) often limit the up‐titration of β‐blockers. Contrarily, ivabradine has no NIE, and enables β‐blockers u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inoue, Tomoko, Matsunaga, Keiji, Kobayashi, Waki, Minamino, Tetsuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984869/ https://www.ncbi.nlm.nih.gov/pubmed/36879680 http://dx.doi.org/10.1002/ccr3.6890

Ejemplares similares

Role of Ivabradine in Patients with Heart Failure with Preserved Ejection Fraction
por: Nadeem, Muhammad, et al.
Publicado: (2020)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
por: Lee, Ying‐Hsiang, et al.
Publicado: (2021)

Effect of ivabradine on ventricular arrhythmias in heart failure patients with reduced ejection fraction
por: Pay, Levent, et al.
Publicado: (2023)

Ivabradine in heart failure patients with reduced ejection fraction and history of paroxysmal atrial fibrillation
por: Lin, Yu‐Sheng, et al.
Publicado: (2022)

Early administration of ivabradine in patients admitted for acute decompensated heart failure
por: Yang, Teng-Yao, et al.
Publicado: (2022)

The role of Ivabradine in Diastolic Heart Failure with preserved Ejection Fraction. A Doppler-Echocardiographic study
por: Cacciapuoti, Federico, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction
por: Krittayaphong, Rungroj, et al.
Publicado: (2019)

The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction
por: Masarone, Daniele, et al.
Publicado: (2021)

Real‐world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction
por: Oh, Jaewon, et al.
Publicado: (2022)

Impact of ivabradine in decompensated heart failure due to cancer therapy‐related cardiac dysfunction
por: Nakano, Yusuke, et al.
Publicado: (2021)

In-hospital Heart Rate Reduction With Beta Blockers and Ivabradine Early After Recovery in Patients With Acute Decompensated Heart Failure Reduces Short-Term Mortality and Rehospitalization
por: Faragli, Alessandro, et al.
Publicado: (2021)

ACUTE MYOCARDITIS AND ACUTE DECOMPENSATED HEART FAILURE WITH REDUCED EJECTION FRACTION IN COVID-19
por: Choudhary, Khushal, et al.
Publicado: (2021)

The prognostic value of heart rate at discharge in acute decompensation of heart failure with reduced ejection fraction
por: Bahouth, Fadel, et al.
Publicado: (2021)

Effect of ivabradine on hospitalization of heart failure patients with reduced left ventricular ejection fraction: A retrospective cohort study
por: Al-Balushi, Sara, et al.
Publicado: (2020)

Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta‐analysis of randomized controlled trials
por: Bryan Richard, Sasmita, et al.
Publicado: (2021)

Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.
por: Bouabdallaoui, Nadia, et al.
Publicado: (2019)

Implication of Ivabradine in Up-titrating Beta-blocker in a Patient with Advanced Heart Failure
por: Hori, Masakazu, et al.
Publicado: (2020)

Clinical Determinants of Quality of Life in Patients With Acute Decompensated Heart Failure With Preserved Ejection Fraction: Insights From the PURSUIT-Heart Failure With Preserved Ejection Fraction Registry
por: Seo, Masahiro, et al.
Publicado: (2022)

Pro‐Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction
por: Abernethy, Abraham, et al.
Publicado: (2018)

Prognostic Importance of Pulmonary Arterial Capacitance in Acute Decompensated Heart Failure With Preserved Ejection Fraction
por: Nakagawa, Akito, et al.
Publicado: (2021)

Ivabradine Ameliorates Cardiac Function in Heart Failure with Preserved and Reduced Ejection Fraction via Upregulation of miR-133a
por: Shao, Shuai, et al.
Publicado: (2021)

A case report of ivabradine used for heart rate control of atrial fibrillation in acute decompensated heart failure
por: Hardison, Edward, et al.
Publicado: (2022)

Effects of Beta-Blockers on Heart Failure with Preserved Ejection Fraction: A Meta-Analysis
por: Liu, Feng, et al.
Publicado: (2014)

Non-withdrawal of beta blockers in acute decompensated chronic and de novo heart failure with reduced ejection fraction in a prospective multicentre study of patients with acute heart failure in the Middle East
por: Abi Khalil, Charbel, et al.
Publicado: (2017)

Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with beta‐blockers
por: Varian, Kenneth D., et al.
Publicado: (2020)

Consensus and development of document for management of stabilized acute decompensated heart failure with reduced ejection fraction in India
por: Kaul, U., et al.
Publicado: (2020)

Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis
por: Basile, Christian, et al.
Publicado: (2023)

Optimal Heart Rate Control Improves Long-Term Prognosis of Decompensated Heart Failure with Reduced Ejection Fraction
por: Tsai, Ming-Lung, et al.
Publicado: (2023)

Ivabradine tolerability in heart failure
por: Birkhoelzer, Sarah, et al.
Publicado: (2018)

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
por: Chatterjee, Saurav, et al.
Publicado: (2013)

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
Publicado: (2013)

Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction
por: Tsujimoto, Tetsuro, et al.
Publicado: (2018)

The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction
por: Xu, Xizhen, et al.
Publicado: (2019)

Comparison of ivabradine plus β-blockers versus β-blocker therapy only
por: Aalbers, J
Publicado: (2010)

Myocardial strain to identify benefit from beta‐blockers in patients with heart failure with reduced ejection fraction
por: Park, Chan Soon, et al.
Publicado: (2022)

Adding ivabradine to beta-blockers in chronic heart failure: Do not rest without lowering the resting heart rate sufficiently
por: Oomman, Abraham, et al.
Publicado: (2018)

Urgent Control of Rapid Atrial Fibrillation by Landiolol in Patients With Acute Decompensated Heart Failure With Severely Reduced Ejection Fraction
por: Iwahashi, Noriaki, et al.
Publicado: (2019)

High Plasma Docosahexaenoic Acid Associated to Better Prognoses of Patients with Acute Decompensated Heart Failure with Preserved Ejection Fraction
por: Matsuo, Naoaki, et al.
Publicado: (2021)

Safety and Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients With Decompensated Heart Failure and Reduced Ejection Fraction
por: Ibrahim, Ayman, et al.
Publicado: (2020)

Clinical and Imaging Parameters Associated With Impaired Kidney Function in Patients With Acute Decompensated Heart Failure With Reduced Ejection Fraction
por: Cho, In-Jeong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5gpt22ro02su1il1j7945ragmo